Metformin-associated lactic acidosis in a burn patient
Abstract
Hyperglycemia commonly is observed as part of the hypermetabolic response to severe burn injury. In routine burn care, physicians use interventions to address and reduce the complications of this stress-induced hyperglycemia. Metformin (1,1-dimethylbiguanide), an orally administered hyperglycemic medication, has been used previously to modulate the stress-induced hyperglycemic response in nondiabetic burn patients. The use of this medication in nonburn diabetic patients has been associated with the development of lactic acidosis. We present an acute burn patient who developed lactic acidosis while receiving metformin for management of his diabetes.
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.